Baker M B, Larson C L, Ushijima R N, Anderson F D
Infect Immun. 1974 Dec;10(6):1230-4. doi: 10.1128/iai.10.6.1230-1234.1974.
The susceptibility of 4- to 6-week-old female white Swiss mice to intravaginal inoculation with Herpesvirus hominis type 2 (HVH2) and the effect of prior intravenous immunization with Mycobacterium bovis (BCG) and/or treatment with specific HVH2 antiserum (SAS) were investigated. Mice inoculated intravaginally developed vaginitis, posterior paralysis, encephalitis, and death. Prior immunization with BCG either had no effect or appeared in some cases to enhance the course of the disease, whereas a single 0.5-ml intravenous injection of SAS provided significant protection. However, synergistic interaction of BCG immunization and treatment with SAS produced the greatest degree of protection in mice challenged intravaginally with HVH2.
研究了4至6周龄雌性瑞士小白鼠经阴道接种人疱疹病毒2型(HVH2)的易感性,以及事先静脉注射牛分枝杆菌(卡介苗)和/或用特异性HVH2抗血清(SAS)治疗的效果。经阴道接种的小鼠出现阴道炎、后肢麻痹、脑炎和死亡。事先接种卡介苗要么没有效果,要么在某些情况下似乎会加重病程,而单次静脉注射0.5毫升SAS则提供了显著的保护作用。然而,卡介苗免疫和SAS治疗的协同相互作用在经阴道接种HVH2攻击的小鼠中产生了最大程度的保护作用。